Instrument Inactif

Communiqués Dermira, Inc.

Actions

US24983L1044

Recherche biotechnologique et médicale

Communiqués

02/03/20	Dermira : Form 15-12B - Securities Registration Termination	PU
20/02/20	Dermira : SEC Filing - S-8 POS	PU
20/02/20	Dermira : SEC Filing - POS AM	PU
20/02/20	Dermira : Lilly Completes Acquisition of Dermira	PR
11/02/20	Dermira : Amended tender offer statement by Third Party	PU
11/02/20	Amended Statement of Ownership: Solicitation	PU
10/02/20	Dermira : Statement of Ownership	PU
10/01/20	(DERM) Alert: Johnson Fistel Investigates Proposed Sale of Dermira, Inc.; Is $19.30 a Fair Price?	PR
10/01/20	DERMIRA, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
10/01/20	Dermira : Lilly Announces Agreement to Acquire Dermira	PR
11/12/19	Dermira : Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
10/12/19	Dermira : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
10/12/19	Dermira : Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis	BU
27/11/19	Dermira : to Participate in December Investor Conferences	BU
14/11/19	Dermira : Presents New Scientific Research Findings from the Lebrikizumab Program at Leading International Itch Conference	BU
13/11/19	Dermira : Elects Halley E. Gilbert to its Board of Directors	BU
11/11/19	Dermira : to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day	BU
08/11/19	Dermira : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
05/11/19	Dermira : Reports Third Quarter 2019 Financial Results and Provides Corporate Update	BU
29/10/19	Dermira : to Report Third Quarter 2019 Results and Host Conference Call on Tuesday, November 5, 2019	BU
17/10/19	Dermira : Presents Data From Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference	BU
10/10/19	Dermira : to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference	BU
09/10/19	Dermira : Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis	BU
08/10/19	Dermira : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
26/09/19	Dermira : to Participate in the 2019 Cantor Global Healthcare Conference	BU